By Y. Grompel. Wheelock College. 2018.
Nonconsecutive patients Results of Type of Study design: case series Nonrandomized halr cervical evidence: Nonmasked reviewers traction for the therapeutic Stad objective of study: Evalua the Nonmasked patients treatmenof use of halr traction and collar in No Validad outcome measures cervical patients with cervical radiculopathy used: radiculopathy: Small sample size retrospective Type of treatment(s): traction for 6 Inadequa length of follow-up review of 81 weeks - additional traction if improving quality 20 mg levitra professional erectile dysfunction medications otc; <80% follow-up patients discount 20mg levitra professional with mastercard erectile dysfunction treatment malaysia. No This paper provides evidence that:75% of patients with mild radiculopathy may Duration of follow-up: 6-12 weeks improve with traction over a six week time frame. In the surgical group, eighpatients had a second operation: six on adjacenlevel, one infection and one plexus exploration. In patients with high pain innsity, low function, high depression and anxiety were seen. The group tread with surgery showed more anxiety and depression if pain continued, implying higher expectations and more disappointmenif ifailed. Abou40% Tis clinical guideline should nobe construed as including all proper methods of care or excluding other acceptable methods of care reasonably direcd to obtaining the same results. Nonconsecutive patients Nonoperative Type of Study design: case series Nonrandomized managemenof evidence: Nonmasked reviewers herniad therapeutic Stad objective of study: reporNonmasked patients cervical success of a conservative No Validad outcome measures inrverbral managemenprogram for cervical used: disc with radiculopathy Small sample size radiculopathy. Yes Conclusions relative to question: This paper provides evidence that:a Duration of follow-up: 3 months multifaced medical/inrventional treatmenprogram is associad with Validad outcome measures used: good outcomes in many patients with none cervical radiculopathy. Yes there is a high incidence of behavioral 20 and emotional dysfunction in cervical 2001;23(8):325- Duration of follow-up: 16 months radiculopathy patients. Nonvalidad outcome measures used: Diagnosis of cervical radiculopathy made by: Clinical exam/history Electromyography Myelogram Tis clinical guideline should nobe construed as including all proper methods of care or excluding other acceptable methods of care reasonably direcd to obtaining the same results. The strongescorrelation between depression and pain was seen in the collar group, possibly because they received less atntion overall. Coping with pain was changed in general into a more passive/escape focused stragy. Function was significantly relad to pain Tis clinical guideline should nobe construed as including all proper methods of care or excluding other acceptable methods of care reasonably direcd to obtaining the same results. Due to the a handheld dynamomer, vigoromer small sample size, one may noand pinchomer. Sensory loss recorded expecto see a difference between the groups on a statistical basis. Nonvalidad outcome measures used: Surgical treatmenresuld in improved outcomes earlier in the Diagnosis of cervical radiculopathy made postoperative treatmenperiod when by: compared with the Clinical exam/history medical/inrventional treatmenlectromyography group. One patienin the physical therapy group and five in the collar group had surgery with Cloward chnique. Strength measurements were all performed by one physical therapiswith standard protocol. Afour month follow-up, pain was improved in the surgical and physical therapy groups, and improvemenin pain scores in the surgical group was significantly betr than in the collar group. The surgical group improved strength a little fasr, buafinal follow-up strength improvemenwas equal across groups. Author conclusions (relative to question): No difference in outcomes afr one year between patients tread with a collar, physical therapy or surgery. Small sample size Prospective, Type of treatment(s): Inadequa length of follow-up multicenr Medical/inrventional treatmenwas <80% follow-up study with nonstandardized in this multicenr trial, Lacked subgroup analysis independenand included medications, sroids, bed Diagnostic method nostad clinical review. Mar 15 chiropractic care, acupuncture and medical/inrventional and surgical 1999;24(6):591- homeopathic medicine. Surgery included treatmenprotocols were Tis clinical guideline should nobe construed as including all proper methods of care or excluding other acceptable methods of care reasonably direcd to obtaining the same results. In general, pain scores were worse in the surgical group preoperatively than in the medical/inrventional treatmengroup. Both groups improved significantly, with grear improvemenseen in the surgical group. Patiensatisfaction, neurological improvemenand functional improvemenwere seen in both groups, with grear improvemenrepord in the surgical group. Although there was improvement, there Tis clinical guideline should nobe construed as including all proper methods of care or excluding other acceptable methods of care reasonably direcd to obtaining the same results. The number returning to work did nodiffer before and afr inrvention in either group despi improved functional ability, implying thathe mosimportanfactor for return to work was work status prior to treatment. Author conclusions (relative to question): Surgery appears to have more success than medical/inrventional treatment, although both help. Despi this, a substantial percentage of patients continue to have severe pain, neurologic symptoms and no work activity. This paper provides evidence Neurosurg Validad outcome measures used: that:suggests thathere are variable Focus. Mar 1 Total number of patients: 86 2008;33(5):458- Number of patients in relevanWork group conclusions: 464. There were some additional procedures aadjacenlevels thawere equivalenfor both groups over two years. In the cage group, 15/40 were investigad with three having same level reoperation and three having adjacenlevel operations.
Cardiovascular outcome trials assessing medication-assisted weight loss are currently ongoing or being planned 20mg levitra professional mastercard erectile dysfunction caused by low blood pressure. Does weight loss improve congestive heart failure and prevent cardiovascular disease events or mortality in patients with congestive heart failure? Is weight loss effective to treat infertility in women with overweight and obesity? Weight loss of more than 5% to 10% is needed for significant improvement in serum testosterone (Grade D) buy levitra professional 20 mg low cost erectile dysfunction tea. Behavioral lifestyle intervention and support should be intensified if patients do not achieve a 2. Does the addition of pharmacotherapy produce greater weight loss and weight-loss maintenance compared with lifestyle therapy alone? Clinicians and their patients with obesity should have available access to all approved medications to allow for the safe and effective individualization of appropriate pharmacotherapy (Grade D). Cardiovascular outcome trials are planned or ongoing for all weight-loss medications except orlistat. Psychotic disorders with or without medications (lithium, atypical antipsychotics, monoamine oxidase inhibitors) • R100. Caution must be exercised in using any weight-loss medication in patients with obesity and a psychotic disorder due to insufficient current evidence assessing safety and efficacy (Grade D). Glyburide, orlistat, and incretin-based therapies should be withheld in cases of prior or current pancreatitis; otherwise there are insufficient data to recommend withholding glyburide for glycemic control, orlistat for weight loss, or incretin- based therapies for glycemic control or weight loss due to concerns regarding pancreatitis (Grade D). Weight-loss medications should not be used in women who are lactating and breast-feeding (Grade D). Patients who have regained excess weight (≥25% of the lost weight) and who have not responded to intensive lifestyle intervention and are not candidates for reoperation may be considered for treatment with liraglutide 1. Note: A de novo evidence-based review of questions pertaining to bariatric surgery was not undertaken. Key recommendations from these guidelines relevant to the questions generated for evidence-based review are copied below. When should bariatric surgery be used to treat obesity and weight-related complications? General Guideline for Diagnosis and Medical Management of Patients with Overweight or Obesity Figure 5 incorporates and summarizes many of the evidence-based recommendations provided in this document. Timothy Garvey reports that he is a consultant for AstraZeneca, Vivus, LipoScience, Daiichi Sankyo, Janssen, Eisai, Takeda, Boehringer Ingelheim, and Novo Nordisk. He is a shareholder with Ionis, Novartis, Bristol-Myers Squibb, Pfizer, Merck, and Eli Lilly. He has received research grants from Merck, Weight Watchers, Sanofi, Eisai, AstraZeneca, Lexicon, Pfizer, Novo Nordisk, and Elcelyx. Hurley reports that he does not have any relevant financial relationships with any commercial interests. Jastreboff reports that she has received research grant support from the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases, the Patterson Trust Award in Clinical Research and an Endocrine Fellows Foundation research grant. Karl Nadolsky reports that he is a shareholder with Leaner Living, Arena, Orexigen, and Vivus. Raymond Plodkowski reports that he is a speaker for Takeda, Novo Nordisk, and Janssen. She is a speaker for Merck, AstraZeneca, Sanofi, Novo Nordisk, and Boehringer Ingelheim/Lilly. She is a shareholder with Eli Lilly, Novo Nordisk, Halozyme, Johnson & Johnson, Bristol-Myers Squibb, Sanofi, Vivus, Pfizer, Medtronic, Merck, Novartis, MannKind, and Teva. Bray reports that he is a speaker for Herbalife International of America, Novo Nordisk, and Takeda. He is also a speaker for Eli Lilly, Novo Nordisk, AstraZeneca, and Boerhinger Ingleheim. Rhoda Cobin reports that she does not have any relevant financial relationships with any commercial interests. He is a consultant and clinical researcher for Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Sanofi, AstraZeneca, Takeda, Merck, Janssen, Freedom Meditech, and GlySens. Ken Fujioka reports that he is a consultant for Novo Nordisk, Takeda, Eisai, Zafgen, and Gelesis. Michael Gonzalez-Campoy reports that he is a consultant for Novo Nordisk and ValenTx. He has received research grant support from Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Sanofi, Eisai, and Ipsen.
Guidelines for the Diagnosis and Treatment of Malaria in Zambia 99 • Report if an increased frequency of a given reaction is observed 20 mg levitra professional for sale erectile dysfunction caused by high blood pressure medication. However buy levitra professional 20mg fast delivery injections for erectile dysfunction forum, if report forms are not available, a copy can be made from the sample form or the form at http://www. National Malaria Health Facility Survey, 2011: Evaluation of the Quality of Malaria-Related Care for Outpatients. Available at: Guidelines for the Diagnosis and Treatment of Malaria in Zambia 102 http://www. Test Response Score Eyes open Spontaneously 4 To speech 3 To pain 2 Never 1 Best verbal Oriented 5 response Confused 4 Inappropriate words 3 Incomprehensible sounds 2 None 1 Best motor Obeys command 5 response Localizes pain 4 Flexion to pain 3 Extension to pain 2 None 1 Guidelines for the Diagnosis and Treatment of Malaria in Zambia 107 Table B2. Caregiver’s face 1 Not directed 0 Verbal response Appropriate cry Moan or inappropriate cry 1 None 0 Best motor Localizes painful stimuli 2 response Withdraws limb from pain 1 Non-specific or absent response 0 Guidelines for the Diagnosis and Treatment of Malaria in Zambia 108 Appendix C: Adverse Medicine Reaction Reporting Form Guidelines for the Diagnosis and Treatment of Malaria in Zambia 109 Appendix D: The Use of Antimalarials for Prophlaxis In Travellers Generic name: Atovaquone-Proguanil Tablet size Adult Pediatric Adverse effects dosage dosage 250 mg One tablet Body weight Not recommended for atovaquone orally once 11–20 kg, prophylaxis for children and 100 mg daily; 1 pediatric weighing < 5 kg, proguanil begin 1–2 table daily; pregnant women, and (adult) days women breastfeeding body weight before infants weighing < 5 kg. Guidelines for the Diagnosis and Treatment of Malaria in Zambia 110 Generic name: Doxycycline Tablet size Adult Pediatric Adverse effects dosage dosage 100 mg One tablet ≥ 8 years Take at approximately the orally once old, 2 mg same time each day while daily; begin per kg of in the malarious area and 1–2 days body for 4 weeks after leaving before weight such areas. Guidelines for the Diagnosis and Treatment of Malaria in Zambia 111 Generic name: Mefloquine Tablet Adult Pediatric Adverse effects size dosage dosage 250 mg One tablet Body weight Begin ≥ 2 weeks before travel orally once ≤ 9 kg, 5 mg to malarious areas. Take weekly; per kg weekly on the same day of the begin 1–2 weekly; week while in the malarious days before area and for 4 weeks after body weight travel and leaving such areas. Telch Laboratory for the Study of Anxiety Disorders, Department of Psychology, The University of Texas at Austin, United States Received 21 August 2007; received in revised form 11 February 2008; accepted 27 February 2008 Abstract Data from 33 randomized treatment studies were subjected to a meta-analysis to address questions surrounding the efficacy of psychological approaches in the treatment of specific phobia. As expected, exposure-based treatment produced large effects sizes relative to no treatment. They also outperformed placebo conditions and alternative active psychotherapeutic approaches. Treatments involving in vivo contact with the phobic target also outperformed alternative modes of exposure (e. Placebo treatments were significantly more effective than no treatment suggesting that specific phobia sufferers are moderately responsive to placebo interventions. Multi-session treatments marginally outperformed single-session treatments on domain-specific questionnaire measures of phobic dysfunction, and moderator analyses revealed that more sessions predicted more favorable outcomes. Contrary to expectation, effect sizes for the major comparisons of interest were not moderated by type of specific phobia. These findings provide the first quantitative summary evidence supporting the superiority of exposure-based treatments over alternative treatment approaches for those presenting with specific phobia. Efficacy of multiple-session exposure treatments relative to single-session treatments........ As with most anxiety disorders, specific phobias show a chronic course with low rates of spontaneous remission (Wittchen, 1988). Despite their circumscribed nature, specific phobia is associated with significant impairment. Wittchen, Nelosn, and Lachner (1998) found that young adults with a diagnosis of specific phobia reported severe impairment in their routine activities during the worst episode of their disorder. Similarly, blood-injury and injection phobias often result in avoidance of medical procedures (Kleinknecht, 1994), and avoidance related to dental phobia can lead significant dental health problems and reductions in quality of life (cf. Treatment utilization There is now compelling evidence suggesting that those suffering from specific phobias are hesitant to seek treatment despite the availability of effective interventions. First, many perceive their phobia as untreatable, or are unaware of effective and available treatments. Second, as many of the available treatments involve direct confrontation with the phobic target, those who are aware of the available treatments may be apprehensive to engage in them. Likewise, Öst (1989) reported that 90% of the spider phobic participants in his study would have refused his single-session treatment if they were told in advance what the treatment entailed. Third, because of the situationally-bound nature of the fear inherent in specific phobia, avoidance of the phobic target may be easily achieved and, thus, serves as a disincentive for seeking treatment. Finally, some individuals may have experienced a failure in conducting self-administered exposure and have therefore concluded that they are unresponsive to this mode of treatment. Those who seek treatment can choose from a number of different interventions, including (but not limited to) cognitive therapy, modeling, imaginal or virtual reality exposure, and direct in vivo exposure. Of all available therapies, exposure therapy is the most widely studied and often considered the first line of treatment for specific phobias (see Barlow, Raffa, & Cohen, 2002; Craske, 1999; Telch, 2004). A recent review article concludes that in vivo exposure may be the most efficacious treatment for specific phobias (Choy, Fyer, & Lipsitz, 2007). However, the authors also note that other modalities of exposure and cognitive restructuring may also be useful in treating certain subtypes of specific phobia. In vivo exposure involves having patients come into direct contact with the feared stimulus, such as a live spider. In vivo exposure has been extensively researched for the treatment of specific phobias including, but not limited to, spiders (Hellstrom & Öst, 1995; Muris, Mayer, & Merckelbach, 1998; Öst, 1996; Öst, Ferebee, & Furmark, 1997; Öst, Salkovskis, & Hellstrom, 1991), snakes (Gauthier & Marshall, 1977; Hepner & Cauthen, 1975), rats (Foa, Blau, Prout, & Latimer, 1977), dogs (Rentz, Powers, Smits, Cougle, & Telch, 2003. Developed by Wolpe (1958, 1973), and based on his theory of “reciprocal inhibition”, systematic desensitization consists of teaching the patient to relax the voluntary muscles during imaginal confrontation with the feared stimulus. Imaginal exposure consists of having the patient imagine a confrontation with the feared stimulus. Unlike systematic desensitization, which dedicated a number of sessions to relaxation training, modern imaginal exposure approaches tend to omit the relaxation component.
10 of 10 - Review by Y. Grompel
Votes: 158 votes
Total customer reviews: 158